Immunoglobulin G1-Kappa/Lambda, Anti-[Homo Sapiens Pdcd1 (Programmed Cell Death 1, Pd1, Pd-1, Cd279) And Havcr2 (Hepatitis A Virus Cellular Receptor 2, T Cell Immunoglobulin And Mucin Domains Family Member 3, Tim3, Tim-3, Timd3, Cd366)], Humanized And Homo Sapiens Monoclonal Antibody, Bispecific, Bivalent
Neoplasm
Explore 889 assets in Neoplasm →Floatz Rating
C33/100
Confidence
Indicative
Sponsor
Presage Biosciences
Modality
monoclonal_antibody
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04541108CT.gov Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa/Lambda, Anti-[Homo Sapiens Pdcd1 (Programmed Cell Death 1, Pd1, Pd-1, Cd279) And Havcr2 (Hepatitis A Virus Cellular Receptor 2, T Cell Immunoglobulin And Mucin Domains Family Member 3, Tim3, Tim-3, Timd3, Cd366)], Humanized And Homo Sapiens Monoclonal Antibody, Bispecific, Bivalent (this asset) | Presage Biosciences | Early P1 | C · 33 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Immunoglobulin G1-Kappa/Lambda, Anti-[Homo Sapiens Pdcd1 (Programmed Cell Death 1, Pd1, Pd-1, Cd279) And Havcr2 (Hepatitis A Virus Cellular Receptor 2, T Cell Immunoglobulin And Mucin Domains Family Member 3, Tim3, Tim-3, Timd3, Cd366)], Humanized And Homo Sapiens Monoclonal Antibody, Bispecific, Bivalent
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Classic Hodgkin Lymphoma | — | P1 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa/Lambda, Anti-[Homo Sapiens Pdcd1 (Programmed Cell Death 1, Pd1, Pd-1, Cd279) And Havcr2 (Hepatitis A Virus Cellular Receptor 2, T Cell Immunoglobulin And Mucin Domains Family Member 3, Tim3, Tim-3, Timd3, Cd366)], Humanized And Homo Sapiens Monoclonal Antibody, Bispecific, Bivalent in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappalambda-anti-homo-sapiens-pdcd1-programmed-cell-death-1-pd1-pd-1-cd279-and-havcr2-hepatitis-a-virus-cellular-receptor-2-t-cell-immunoglobulin-and-mucin-domains-family-member-3-tim3-tim-3-timd3-cd366-humanized-and-homo-sapiens-monoclonal-antibody-bispecific-bivalent-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →